Related Experiment Video
Updated: Jan 31, 2026

Author Spotlight: Developing Innovative Therapeutic Strategies for Hemorrhagic Shock Research
Published on: March 22, 2024
Pediatric Hemorrhagic Moyamoya Disease: Clinical Course, Treatment, and Outcomes
Qingbao Guo1, Manli Xie2, Jingchun Wang1
1Department of Neurosurgery, Xi'an No.9 Hospital Shaanxi, China.
Background And Objectives:
Pediatric hemorrhagic moyamoya disease (MMD) is a critical subtype associated with high morbidity; however, hemorrhage-specific prognostic factors remain poorly defined. The aim of this study was to define the clinical course, identify factors associated with hemorrhagic presentation and recurrence, and evaluate long-term outcomes in a large pediatric cohort.
Methods:
This retrospective cohort study included children diagnosed with MMD between 2003 and 2023. Hemorrhagic MMD was defined as acute intracranial hemorrhage on CT/MRI within 72 hours of symptom onset, excluding traumatic or aneurysmal causes. Standardized data collection encompassed Suzuki staging, posterior communicating artery (PcomA) and anterior choroidal artery (AChA) dilatation, modified Rankin Scale (mRS) scores at admission and follow-up, and recurrence events. Multivariable logistic regression and Cox proportional hazards models were used to identify factors associated with hemorrhagic MMD and stroke recurrence.
Results:
Among 1,446 pediatric patients with MMD, 117 had hemorrhagic presentation. The hemorrhagic cohort was significantly older (mean age 10.9 ± 4.1 years vs 7.6 ± 4.5 years, p < 0.001) and had a higher proportion of female patients (68.4% vs 50.0%, p < 0.001). Factors independently associated with hemorrhagic MMD included AChA dilatation (adjusted odds ratio [aOR] 5.95, 95% CI 3.56-9.92, p < 0.001), PcomA dilatation (aOR 4.23, 95% CI 2.48-7.20, p < 0.001), and admission mRS score ≥2 (aOR 2.38, 95% CI 1.44-3.96, p < 0.001). The hemorrhagic group showed higher rates of hematoma recurrence (7.7% vs 0.8%, p < 0.001). AChA dilatation was strongly associated with recurrent hematoma (hazard ratio [HR] 8.85, 95% CI 3.06-25.58, p < 0.001). Admission mRS score ≥2 was significantly associated with all recurrence subtypes: stroke (HR 13.32), hematoma (HR 5.58), and infarction (HR 52.16; all p ≤ 0.002). The Kaplan-Meier analysis confirmed markedly reduced 8-year hematoma recurrence-free survival in hemorrhagic MMD (50% vs >80% in ischemic, p < 0.0001).
Discussion:
Hemorrhagic MMD is an aggressive subtype characterized by posterior collateral vulnerability, female predominance, and older age. Admission mRS score ≥2 and AChA dilatation are key factors strongly associated with adverse outcomes. Conventional angiographic classification does not demonstrate a significant association with hemorrhage outcome; assessment of the posterior circulation is critical for stratifying patient outcomes and guiding early intervention.
Insights
Hemorrhagic moyamoya disease (MMD) in children is aggressive, often seen in older females. Anterior choroidal artery dilatation and higher admission disability scores predict worse outcomes and recurrence.
Area of Science:
- Neuroscience
- Pediatric Neurology
- Vascular Neurology
Background:
- Pediatric hemorrhagic moyamoya disease (MMD) presents a significant clinical challenge due to high morbidity.
- Prognostic factors specifically related to hemorrhagic MMD in children are not well-defined.
- Understanding these factors is crucial for improving patient outcomes and guiding treatment strategies.
Purpose of the Study:
- To define the clinical course of pediatric hemorrhagic MMD.
- To identify factors associated with hemorrhagic presentation and recurrence.
- To evaluate the long-term outcomes in a large pediatric cohort with MMD.
Main Methods:
- Retrospective cohort study of pediatric MMD patients (2003-2023).
- Hemorrhagic MMD defined by acute intracranial hemorrhage (excluding trauma/aneurysm).
- Data included Suzuki staging, PcomA/AChA dilatation, mRS scores, and recurrence events; analyzed using logistic regression and Cox models.
Main Results:
- Hemorrhagic MMD cohort (117/1446 patients) was older and predominantly female.
- Independent predictors for hemorrhagic MMD: AChA dilatation (aOR 5.95), PcomA dilatation (aOR 4.23), and admission mRS ≥2 (aOR 2.38).
- AChA dilatation strongly predicted recurrent hematoma (HR 8.85); admission mRS ≥2 predicted all recurrence types (stroke, hematoma, infarction).
Conclusions:
- Hemorrhagic MMD is an aggressive subtype with posterior collateral vulnerability, female predominance, and older age at presentation.
- Admission mRS score ≥2 and AChA dilatation are critical indicators of adverse outcomes.
- Focus on posterior circulation assessment is vital for outcome stratification and early intervention in pediatric MMD.
More Related Videos
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Treatment
Chronic Kidney Disease II: Clinical Manifestations
Coronary Artery Disease III: Clinical Manifestations
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

